Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Current Assets (2016 - 2025)

Kiora Pharmaceuticals' Current Assets history spans 11 years, with the latest figure at $21.7 million for Q4 2025.

  • For Q4 2025, Current Assets fell 26.79% year-over-year to $21.7 million; the TTM value through Dec 2025 reached $21.7 million, down 26.79%, while the annual FY2025 figure was $21.7 million, 26.79% down from the prior year.
  • Current Assets reached $21.7 million in Q4 2025 per KPRX's latest filing, down from $22.7 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $33.5 million in Q1 2024 to a low of $4.4 million in Q2 2022.
  • Average Current Assets over 5 years is $15.7 million, with a median of $9.0 million recorded in 2023.
  • Peak YoY movement for Current Assets: plummeted 44.19% in 2022, then skyrocketed 526.97% in 2024.
  • A 5-year view of Current Assets shows it stood at $9.0 million in 2021, then fell by 26.32% to $6.6 million in 2022, then decreased by 28.47% to $4.7 million in 2023, then surged by 526.97% to $29.7 million in 2024, then dropped by 26.79% to $21.7 million in 2025.
  • Per Business Quant, the three most recent readings for KPRX's Current Assets are $21.7 million (Q4 2025), $22.7 million (Q3 2025), and $24.7 million (Q2 2025).